国产中文无码av每日更新在线观看, 亚洲天堂中文字幕一区二区三区免费, 国产口爆吞精在线观视频-黄色国产, 92福利-国内精品久久久久久99,亚洲成AV人A片不卡无码,浪潮AV无码专区,老熟女败火白浆,中文字幕日产av,色情日本免费看大片

更新于 6月26日

(高級(jí))醫(yī)學(xué)科學(xué)顧問(wèn) (Sr)Medical Scientific Advisor-RWE

2.5-3萬(wàn)·13薪
  • 北京朝陽(yáng)區(qū)
  • 3-5年
  • 碩士
  • 全職
  • 招1人

雇員點(diǎn)評(píng)標(biāo)簽

  • 工作環(huán)境好
  • 同事很nice
  • 團(tuán)隊(duì)執(zhí)行強(qiáng)
  • 氛圍活躍
  • 人際關(guān)系好
  • 交通便利
  • 晉升機(jī)會(huì)多
  • 管理人性化

職位描述

藥物研究上市后
Accountabilities:
1、Clinical development strategy set up: Clinical development plan, medical part of protocol, cross functional alignment.
2、Medical dossier preparation: Medical part of IB, CSR etc.
3、Medical monitoring: Medical review including AE/SAE, protocol deviation, data review. Medical query from PI & CRA.
4、External key stakeholder communication: Communication with external key stakeholder such as TAE, CDE, NMPA etc. with medical support.
5、Cross functional cooperation: Close cooperate with internal stakeholders such as HQ RWE team, PV team, statistic team, strategic team and compliance team etc.
Knowledge/ Academic Qualification:
1、Master’s degree or above in clinical medicine.
Skills:
1、Clinical medical education background preferred
2、Complete GCP training.
3、Fluent both in oral and written English and Chinese
4、Excellent communication skills
5、Familiar with clinical study flow and related policy
Experience:
1、Experience of medical physician role for at least 1 clinical trial is mandatory.
2、More than three years’ experience in R&D pharma. MSA or CRO experience preferred
3、Clinical doctor experience, esp. oncology field experience preferred
Competency:
1、Develop study plan and protocol
2、Knowledge of drug development and clinical trial process
3、Proactive attitude and open minded
4、Facing challenge actively and results driven

工作地點(diǎn)

北京朝陽(yáng)區(qū)施維雅(天津)制藥有限公司

職位發(fā)布者

HR/人事經(jīng)理

當(dāng)前在線
立即溝通
公司Logo法國(guó)施維雅
施維雅是一家由非盈利性基金管理的國(guó)際制藥公司,總部位于法國(guó)(敘雷訥),業(yè)務(wù)遍及全球150個(gè)國(guó)家。全球共計(jì)21,800名員工共同致力于推進(jìn)醫(yī)療變革創(chuàng)新升級(jí),為患者提供高質(zhì)量藥物與關(guān)鍵性健康解決方案。集團(tuán)平均每年將20%品牌藥物收入投入于藥品研發(fā)。同時(shí),集團(tuán)長(zhǎng)期與學(xué)術(shù)機(jī)構(gòu)、制藥企業(yè)以及生物技術(shù)公司保持開放的合作,從而加速醫(yī)療創(chuàng)新、惠及更多患者,創(chuàng)造一個(gè)可以確保所有人獲得優(yōu)質(zhì)健康服務(wù)的世界。集團(tuán)在心血管與代謝疾病、腫瘤學(xué)、神經(jīng)科學(xué)以及免疫炎癥四個(gè)領(lǐng)域的持久承諾是集團(tuán)持續(xù)增長(zhǎng)的動(dòng)力。
公司主頁(yè)